# Abbott India (ABBOTINDIA) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/abbotindia

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹26,380
- Change: -0.85%
- As of: 2026-11-06
- 1D return: -0.85%
- 5D return: +2.91%
- 1M return: +3.13%
- Latest complete quarter: —

## Faxioms Analysis

_As of 2026-11-06_

### Technical Outlook

As of the close on 5 November 2026, ABBOTINDIA trades at ₹26,605.00, reflecting a short-term bounce within a broader structural downtrend. The daily chart shows price above the 20-period and 50-period EMAs and SMAs, with the Supertrend signaling bullish, yet the ADX of 17.2 indicates weak trend conviction. This contrasts sharply with the monthly horizon, where the price remains below all moving averages and the Supertrend is bearish (ADX 7.89), confirming the longer-term weakness. Participation was mixed: an extreme volume spike accompanied a +5.1% gain on 4 November, followed by high participation without clear direction on 3 November, and a moderate -1.9% decline on 5 November with low volume. The stock sits in the upper-middle of its 20-day range (+69.8%) but remains significantly off its highs (-25.4% from available high). Immediate resistance lies near ₹26,793.33 (pivot, +0.71%), while support is closely held at ₹26,591.64 (-0.05%).

- Trend Divergence: Daily indicators are bullish (price above 20/50 EMA/SMA, Supertrend up) but monthly structure remains bearish (price below all MAs, Supertrend down; ADX 7.89).
- Range Position: Trading at ₹26,605.00, the stock is +69.8% into its 20-day range but -25.4% from its available high, indicating recent strength against a longer-term backdrop.
- Key Levels: Immediate resistance at ₹26,793.33 (+0.71%); immediate support at ₹26,591.64 (-0.05%). A break above ₹26,793 could target ₹27,776.67 (+4.40%).
- Momentum & Risk: ADX readings are weak across daily (17.2), weekly (10.71), and monthly (7.89) timeframes. Annualized volatility is +23.3%, with a current drawdown of -25.4%.

- Morning Star
- Doji
- Inside Bar

### Fundamentals

Abbott India demonstrates a robust operating trajectory with consistent top-line and bottom-line growth. For the trailing twelve months (TTM) ending around November 2026, sales reached ₹7,004 crore, reflecting a 3-year compounded annual growth rate of 9% and a 5-year CAGR of 10%. Net profit for the TTM period stood at ₹1,615 crore, up from ₹1,552 crore in FY2026 and ₹1,414 crore in FY2025, supporting a 3-year compounded profit growth of 18%. The company maintains exceptional capital efficiency, with Return on Equity (ROE) holding steady at 34-35% over the last five years and Return on Capital Employed (ROCE) remaining high at 45-46% through March 2026.

Earnings quality is strong, evidenced by cash flow from operations (CFO) of ₹1,319 crore in FY2026, representing a CFO-to-EBITDA conversion ratio of 98%. The balance sheet remains conservative; borrowings decreased slightly to ₹172 crore in March 2026 from ₹197 crore in March 2025, while fixed assets grew significantly to ₹331 crore, indicating ongoing capacity expansion. Working capital management improved markedly, with the Cash Conversion Cycle stabilizing at 3 days in March 2026 after a spike in FY2025, driven by a reduction in debtor days to 19. Inventory days increased to 94, suggesting inventory buildup may warrant monitoring alongside receivables collection.

Shareholding patterns show stable promoter holding at 74.99%, with Foreign Institutional Investors (FIIs) increasing their stake to 0.40% in September 2026 from 0.16% previously. The most important next checkpoint is the sustainability of working capital metrics, specifically whether inventory days remain elevated or normalize as the company integrates its expanded fixed asset base.

- Sales grew 9% (3Y CAGR) and 10% (5Y CAGR), with TTM sales at ₹7,004 crore and net profit at ₹1,615 crore.
- Capital efficiency remains elite: ROE is 34-35% and ROCE is 45-46%, supported by low borrowings of ₹172 crore.
- Cash conversion is strong with 98% CFO/EBITDA ratio in FY2026, though inventory days rose to 94 in March 2026.
- Promoter holding is stable at 74.99%; FII stake increased to 0.40% in Sep 2026.

### Bear Case

Technical indicators for Abbott India reflect a deteriorating medium-term trend and significant downside risk. While the daily chart shows a bullish super-trend, the weekly and monthly trends are bearish, with the monthly ADX at 7.89 indicating weak momentum. The stock has experienced a maximum drawdown of -29.8% and is currently in a -25.4% drawdown from its peak. Year-to-date returns are negative at -6.6%, with a one-year return of -9.4%. Trading volume is low, with only 10,067 trades on the latest session, suggesting limited liquidity or interest. Support levels are close, with immediate support at ₹26,591.64 (0.05% below current price) and further support at ₹26,136.67 (1.76% below).

- Medium-term technicals are bearish: Weekly and monthly super-trends are down, with monthly ADX at 7.89 signaling weak momentum.
- Significant drawdown risk: Current drawdown is -25.4%, near the maximum historical drawdown of -29.8%.
- Negative period returns: YTD return is -6.6% and 1-year return is -9.4%, underperforming broader market trends.
- Low liquidity: Latest session recorded only 10,067 trades and a turnover of ₹5.2 crore, indicating thin trading activity.

- [Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return](https://economictimes.indiatimes.com/markets/stocks/news/pills-are-paying-off-pharma-stocks-lead-2026-rally-with-up-to-112-return/articleshow/135561757.cms)
- [Stock Market LIVE: GIFT Nifty jumps 300 pts as Brent crude slips below $100; Kospi tumbles 4%](https://www.business-standard.com/markets/news/stock-market-live-november-5-nse-bse-sensex-today-nifty50-gift-nifty-crude-oil-prices-ipo-today-126110500085_1.html)

### FAQs

**What is the current market valuation and trading range for ABBOTINDIA?**

As of 5 November 2026, Abbott India (NSE) has a market capitalization of ₹57,628.1 crore. The stock closed at ₹26,605 after opening at ₹27,210 on a turnover of ₹5.22 crore. Immediate resistance sits at ₹26,793 (0.71% above), while support is observed at ₹26,592 (0.05% below).

**How has ABBOTINDIA performed over different time horizons?**

The stock is down -6.6% year-to-date and -9.4% over the past year. Short-term momentum shows a +4.9% gain over the last 10 days and +1.4% over the last month. However, the stock remains in a significant drawdown, with a current decline of -25.4% from its peak.

**What do technical indicators suggest about the trend direction?**

Daily charts show a bullish super-trend with strong upward directional movement (+DI: 27.9 vs -DI: 16.06). Conversely, weekly and monthly trends are bearish, with super-trends indicating downward pressure. This divergence suggests short-term buying interest against a longer-term downtrend.

**Is there sector-level context affecting pharmaceutical stocks like ABBOTINDIA?**

Yes. In 2026, India's pharmaceutical sector is the best-performing equity segment, up 27% year-to-date. Analysts attribute this to resilient domestic demand and improving US margins. However, some caution that high valuations may limit further market-beating gains compared to other sectors.

- [Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return](https://economictimes.indiatimes.com/markets/stocks/news/pills-are-paying-off-pharma-stocks-lead-2026-rally-with-up-to-112-return/articleshow/135561757.cms)
- [Stock Market LIVE: GIFT Nifty jumps 300 pts as Brent crude slips below $100; Kospi tumbles 4%](https://www.business-standard.com/markets/news/stock-market-live-november-5-nse-bse-sensex-today-nifty50-gift-nifty-crude-oil-prices-ipo-today-126110500085_1.html)
## Technical analytics

- As of: 2026-11-06
- Daily trend: Weak Uptrend
- Weekly trend: Weak Downtrend
- Pivot point: ₹26,770
- Risk regime: Price Risk Requires Attention

### Support levels
- 26427.5
- 25829.375
- 25670

### Resistance levels
- 28521.5515625
- 29900.95
- 30550.3251953125

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | -0.85% |
| return_10 | +5.39% |
| return_1m | +1.01% |
| return_1y | -10.44% |
| return_20 | +3.13% |
| return_3m | -5.30% |
| return_5 | +2.91% |
| return_6m | +0.30% |
| return_since_start | -12.13% |
| return_ytd | -7.39% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | elevated_risk |
| label | Price risk requires attention |
| summary | Recent drawdown or price variability is high enough to warrant closer monitoring. |
| maximum_drawdown | -29.83% |
| annualized_volatility | +23.25% |

## Quarterly financials

Quarterly financials are not currently available.

## Official filings

No official filings are currently available.

## News and market events

- 2026-11-07 — MONEYCONTROL: **Buy Abbott India; target of Rs 33500: ICICI Securities** — ICICI Securities has issued a 'Buy' recommendation for Abbott India with a target price of Rs 33,500. The article provides this specific investment advice from the brokerage firm regarding the listed entity. — [Source](https://www.moneycontrol.com/news/business/earnings/buy-abbott-india-target-of-rs-33500-icici-securities-14074292.html)
- 2026-11-05 — Economic Times: **Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return** — India's pharmaceutical sector has emerged as the best-performing equity segment in 2026, with the sectoral index rising 27% year-to-date and leading stocks like Laurus Labs delivering returns of up to 112%. This outperformance is attributed to resilient domestic demand, improving US business margins, and new product opportunities such as semaglutide, which have supported an underlying earnings recovery. While analysts view the rally as sustainable due to predictable earnings, some caution that valuations may limit further market-beating gains compared to other sectors. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/pills-are-paying-off-pharma-stocks-lead-2026-rally-with-up-to-112-return/articleshow/135561757.cms)
- 2026-11-05 — BUSINESS: **Stock Market LIVE: GIFT Nifty jumps 300 pts as Brent crude slips below $100; Kospi tumbles 4%** — GIFT Nifty indicated a gap-up open for the Nifty50 index, surging 342 points to 24,311, as Brent crude prices slipped below $100 amid expectations of a faster resolution to the West-Asia conflict following the US midterm election results. Asian markets were mixed with traders rotating out of semiconductor shares into consumer and financial sectors, while Japan’s Nikkei 225 and KOSPI fell 0.39 per cent and 3.6 per cent respectively. Additionally, Bombay Coated & Special Steels is set to debut on exchanges on Thursday, and several companies including Aadhar Housing Finance and Bharti Airtel are — [Source](https://www.business-standard.com/markets/news/stock-market-live-november-5-nse-bse-sensex-today-nifty50-gift-nifty-crude-oil-prices-ipo-today-126110500085_1.html)
- 2026-09-24 — The Hindu: **Lokesh meets heads of top companies, seeks investments in Andhra Pradesh** — Lokesh meets global heads to seek investments and manufacturing centers in Andhra Pradesh across IT, medical devices, GCCs, and related sectors. — [Source](https://www.thehindu.com/news/national/andhra-pradesh/lokesh-meets-heads-of-top-companies-seeks-investments-in-andhra-pradesh/article71504594.ece)
- 2026-09-22 — REDIFF.COM: **Top Pharma Firms Maintain Volume Growth Amid Market Shift to Chronic Therapies** — India's 10 largest pharmaceutical companies have consistently maintained positive average volume growth throughout 2026, while smaller rivals have experienced more erratic performance, driven by a market shift towards chronic and sub-chronic therapies. — [Source](https://www.rediff.com/business/report/indias-top-10-pharma-companies-sustain-volume-growth-outperforming-smaller-rivals/20260922.htm)
- 2026-09-15 — BUSINESS: **Abbott India Ltd rises for third straight session** — Abbott India Ltd is quoting at Rs 26155, up 2.37% on the day as on 12:49 IST on the NSE. The stock is down 15.44% in last one year as compared to a 7.58% jump in NIFTY and a 18.39% jump in the Nifty Pharma index. — [Source](https://www.business-standard.com/markets/capital-market-news/abbott-india-ltd-rises-for-third-straight-session-126091500481_1.html)
- 2026-09-14 — Economic Times: **What’s in a word? For India's FMCG brands, it's increasingly everything** — Indian regulators are intensifying scrutiny over misleading food product claims. Companies now face legal challenges for unsubstantiated marketing statements. New front-of-pack warning labels are proposed for unhealthy packaged foods. This regulatory push aims to provide consumers with clearer product information. Companies are consequently allocating more resources towards compliance and quality checks. — [Source](https://economictimes.indiatimes.com/industry/cons-products/food/fssai-crackdown-on-misleading-food-claims-fmcg-companies-face-scrutiny/articleshow/134234919.cms)
- 2026-08-12 — CNBC-TV18: **Stocks to Watch for August 13: Tata Motors, Apollo Hospitals, UltraTech Cement, Lenskart and more** — Stocks of Astral, Lenskart, Tata Motors, IRCON and other companies will be in focus on Wednesday as these companies reported their June quarter earnings after market hours on Tuesday. Investors will also watch Asian Energy Services, Awfis Space Solutions, Balaji Telefilms and others, which are scheduled to announce their results tomorrow. — [Source](https://www.cnbctv18.com/photos/market/stocks-to-watch-for-august-13-tata-motors-ircon-astral-lenskart-and-more-19967707.htm)
- 2026-08-12 — CNBC-TV18: **Q1 Results Live Updates: Ircon International profit down 43%, Astral EBITDA up 23%** — Q1 Results LIVE Updates: Apollo Hospitals and Grasim are among the final Nifty 50 names that will be reporting their results today along with broader market names such as HAL, IRCTC, IRCON, Lenskart, Astral, Tata Motors CV, among others. Manappuram, PI Industries, Bata India, Senco Gold, and others will also be reacting to their results. Watch this space for all the LIVE Q1 result updates. — [Source](https://www.cnbctv18.com/market/q1-results-live-updates-today-hal-apollo-hosp-manappuram-irctc-ircon-lenskart-grasim-pi-ind-astral-share-price-liveblog-19967133.htm)
- 2026-07-24 — Mint: **Trump's tariff policy: Abbott India, Ajanta Pharma to Alembic — pharma stocks crash up to 4%** — Pharma stocks dipped on July 24 after President Trump announced a phased tariff plan for imported generic medicines, raising concerns for Indian exporters. Abbott India led losses at 3.69%, prompting fears over the future of American production and long-term impacts on stocks. — [Source](https://www.livemint.com/market/stock-market-news/trumps-tariff-policy-abbott-india-ajanta-pharma-to-alembic-pharma-stocks-crash-up-to-4-11784869745089.html)
- 2026-07-23 — Economic Times: **Dividend alert! Last day to buy Bharti Airtel, Hero MotoCorp, among 43 stocks for dividend payout worth Rs 1,127** — As per Sebi's T+1 settlement cycle, investors must buy a company's shares at least one trading day before the record date to ensure the shares are credited to their demat accounts in time, and they become eligible for the corporate action — [Source](https://economictimes.indiatimes.com/markets/stocks/news/dividend-alert-last-day-to-buy-bharti-airtel-hero-motocorp-among-43-stocks-for-dividend-payout-worth-rs-1127/articleshow/132570497.cms)
- 2026-07-22 — The Hindu: **US tariff threat drags Nifty Pharma 1.4% lower; Lupin, Auropharma lead decline** — US tariff threats lead to a 1.4% drop in Nifty Pharma, with Lupin and Auropharma experiencing significant declines. — [Source](https://www.thehindubusinessline.com/markets/stock-markets/us-tariff-threat-drags-nifty-pharma-14-lower-lupin-auropharma-lead-decline/article71252663.ece)
- 2026-07-22 — News18: **Lupin, Aurobindo, Cipla Fall Up To 2.9%: Pharma Stocks Under Pressure As Trump's Tariff Roadmap Rattles Sentiment** — Lupin falls 2.88%, Aurobindo Pharma declines 2.73%, Alkem Laboratories slips 2.44%, Zydus Lifesciences drops 2.20%, while Cipla slips 2.09%. — [Source](https://www.news18.com/business/markets/lupin-aurobindo-cipla-fall-up-to-2-9-pharma-stocks-under-pressure-as-trumps-tariff-roadmap-rattles-sentiment-ws-l-10226502.html)
- 2026-07-19 — Economic Times: **Bonus, dividends and stock splits: Bharti Airtel, Hero MotoCorp among 88 stocks turning ex-date this week. Do you own any?** — Investors must hold shares in their demat accounts on the respective record dates to be eligible. Here is the complete day-wise list of key corporate actions to track. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/bonus-dividends-and-stock-splits-bharti-airtel-hero-motocorp-among-88-stocks-turning-ex-date-this-week-do-you-own-any/articleshow/132491671.cms)

## Business profile

**Strategic vision:** Develops, manufactures, and markets branded generic medicines in India.

### Business segments
- **Primary Care:** Focuses on general medicine, including pain management, gastroenterology, and anti-infectives.
- **Specialty Care – Metabolics & Urology:** Focuses on therapies for thyroid disorders, diabetes care, weight management, and urological health.
- **Specialty Care – Neuroscience:** Manages a specialized portfolio of psychiatric and neurological treatments.
- **Hospital Care:** Focuses on specialized formulations for anesthesiology and neonatology utilized within hospital settings.

### Competitive strengths
- Focus on branded generic medicines tailored to the domestic healthcare market.
- Extensive nationwide distribution network.
- Specialized divisions targeting distinct therapeutic areas.

## Related stocks

- [Ajanta Pharma Limited (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +0.55%
- [Alkem Laboratories Limited (Healthcare)](https://faxioms.com/stocks/alkem) — +2.06%
- [Aurobindo Pharma Limited (Healthcare)](https://faxioms.com/stocks/auropharma) — +0.84%
- [Biocon Limited (Healthcare)](https://faxioms.com/stocks/biocon) — +0.86%
- [Cipla Limited (Healthcare)](https://faxioms.com/stocks/cipla) — +0.49%

## Freshness and sources

- Data as of: 2026-11-06
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/abbotindia
Markdown representation: https://faxioms.com/stocks/abbotindia?render=md